Corgi All World 2x Daily ETF(WX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

WX Corgi All World 2x Daily ETF

交易中 10-01 14:11:24 EDT

24.00

+0.00

0.00%

最高24.00	最低24.00	成交量255.00
今开24.00	昨收24.00	日振幅0.00%
总市值60.00万	流通市值60.00万	总股本2.50万
成交额6,067	换手率1.02%	流通股本2.50万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"WX","market":"US","secType":"STK","nameCN":"Corgi All World 2x Daily ETF","latestPrice":23.9994,"timestamp":1790874075071,"preClose":23.9994,"halted":0,"volume":255,"delay":0,"changeRate":0,"floatShares":25000,"shares":25000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"10-01 14:11:24 EDT","open":23.9994,"high":23.9994,"low":23.9994,"amount":6066.9906,"amplitude":0,"askPrice":23.88,"askSize":300,"bidPrice":23.81,"bidSize":300,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"exchange":"CBOE","adjPreClose":23.9994,"nav":24.15,"aum":603750,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.26,"preClose":23.9994,"latestTime":"16:10 EDT","volume":6,"amount":144.5176,"timestamp":1790799005449,"change":0.2606,"changeRate":0.010859,"amplitude":0},"volumeRatio":2.338589},"requestUrl":"/m/hq/s/WX","defaultTab":"news","newsList":[{"id":"2672758061","title":"创新药出海之后，CXO能否接住订单复苏？","url":"https://stock-news.laohu8.com/highlight/detail?id=2672758061","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672758061?lang=zh_cn&edition=full","pubTime":"2026-10-01 16:18","pubTimestamp":1790842680,"startTime":"0","endTime":"0","summary":"9月医药板块的重估，起点是创新药出海交易的密集落地，真正决定行情能否继续的，却是一个更具体的问题：BD交易能否转化为CXO产业链的订单、收入和利润？公开资料显示，国家药监局9月14日披 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261001/c680429674.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261001/c680429674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LNGR","06978","IBBQ","WX","159992","CXO","MEDX","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671271309","title":"科创板收评：权重股拖累科创50指数下行 创新药械、CXO板块逆势爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2671271309","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671271309?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:04","pubTimestamp":1790751854,"startTime":"0","endTime":"0","summary":"今日，科创50指数收跌2.58%。盘面上，寒武纪、中芯国际、海光信息、澜起科技等权重股普遍下挫。分行业来看，创新药械、CXO板块逆势爆发，康希诺、泰诺麦博20cm涨停，南模生物涨超19%，近岸蛋白涨超13%，洁特生物涨超12%。半导体板块情绪低迷，芯原股份跌超11%，气派科技、杰华特跌超7%，华峰测控跌超6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202609303887676434.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202609303887676434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["KSTR","159371","399265","WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671725228","title":"盈利修复叠加出海提速，创新药与CXO投资机遇受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2671725228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671725228?lang=zh_cn&edition=full","pubTime":"2026-09-30 07:14","pubTimestamp":1790723656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WX","CXO","LNGR","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670224407","title":"CXO概念活跃 华神科技涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2670224407","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670224407?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:32","pubTimestamp":1790559162,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669488353","title":"港股医药实力抗跌！CXO再扛旗，核心ETF（159137）逆市收红，金斯瑞创5年新高！两个问题引发关注……","url":"https://stock-news.laohu8.com/highlight/detail?id=2669488353","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669488353?lang=zh_cn&edition=full","pubTime":"2026-09-23 19:17","pubTimestamp":1790162220,"startTime":"0","endTime":"0","summary":"AI制药产业链上游CXO全天强势，百奥赛图-B领涨近5%，金斯瑞生物科技再涨3.21%创5年新高！港股通医疗ETF华宝标的指数AI制药含量近70%，盘中冲高1.4%，收涨0.1%。图：港股通创新药ETF华宝近6月走势近期港股创新药链相对强势，回顾行情结构，两个问题引发关注：其一，AI制药热度走高，为什么CXO涨势更优。港股通创新药ETF华宝：标的指数100%布局创新药研发类公司，7成仓位押注创新药研发龙头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-23/doc-inisvivx8562452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","159137","BK4550","FDN","BK4585","BK4588","159718","WX","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139506","title":"医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139506?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:10","pubTimestamp":1789956632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初走高，截至发稿，昭衍新药（06127）涨6.14%，药明生物（02269）涨4.97%，金斯瑞生物科技（01548）涨4.47%，维亚生物（01873）涨3.75%，药明康德（02359）涨3.40%，泰格医药（03347）涨2.52%，康龙化成（03759）涨2.64%。中邮证券研究指，2026中报看，CXO行业是医药行业中最亮眼板块之一。数据上看，CDMO龙头、安评及临床CRO是三条景气主线。估值上看，CDMO龙头公司按2027PE仍处于合理区间，CRO环节公司报表仍处修复阶段，新签高毛利订单待转化，因此表观估值较高，但预计随着订单的逐渐周转快速消化。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CXO","LU0348766576.USD","LU0516423091.SGD","01548","HK0000306701.USD","LU0052750758.USD","LU2242644610.SGD","SG9999002463.SGD","BK1583","LU0516423174.USD","LU0039217434.USD","BK1515","LU0516422440.USD","LU0043850808.USD","06127","LU1880383366.USD","03759","09939","LU0181495838.USD","LU0516422952.EUR","03347","LU0029874905.USD","LU0320764599.SGD","HK0000320223.HKD","LU0051755006.USD","02269","LU0359201612.USD","02359","LU1242518857.USD","01873","BK1141","LU0029874061.USD","LU0307460666.USD","LU1794554557.SGD","LU2125910500.SGD","WX","LU0456846285.SGD","BK1589","BK1161","LU0359202008.SGD","LU0588546209.SGD","603127","LU3063872942.SGD","LU0561508036.HKD","LU0540923850.HKD","BK1610","KURE","LU0348825331.USD","LU0516422366.SGD","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919819","title":"CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919819","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919819?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:46","pubTimestamp":1789695974,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块上扬，昭衍新药 涨5.64%，金斯瑞生物科技涨4.78%，维亚生物涨2.15%，泰格医药涨1.93%，药明生物涨1.80%，凯莱英涨1.79%，药明康德涨1.01%，百济神州涨0.95%。中信建投近日研报指，CXO是创新药产业链专业化分工的重要载体，也是连接药物研发与商业化生产的关键基础设施。随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991930","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01873","BK1588","LU1242518931.SGD","LU0348735423.USD","01548","IE00B0JY6N72.USD","LU1251922891.USD","LU0228659784.USD","LU0029874905.USD","LU1719994722.HKD","LU0029874061.USD","BK1610","603127","02359","LU0359202008.SGD","LU0456846285.SGD","LU2039709279.SGD","LU0320764599.SGD","LU2242644610.SGD","LU3063872942.SGD","LU0051755006.USD","03347","LU0181495838.USD","BK0216","06127","LU1688375341.USD","LU0634319403.HKD","LU0128522744.USD","LU0348827113.USD","LU0561508036.HKD","06160","LU0320764243.SGD","LU1880383366.USD","LU0516423174.USD","02269","LU0348825331.USD","LU0856984785.SGD","LU1242518857.USD","SG9999002562.SGD","LU0469268626.HKD","06821","LU0052750758.USD","LU0828237510.HKD","CXO","BK1521","WX","KURE","LU0588546209.SGD","LU0039217434.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668930626","title":"港股异动 | CRO概念股涨幅居前 AIDD利好催化密集 CXO板块景气度明确上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2668930626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668930626?lang=zh_cn&edition=full","pubTime":"2026-09-17 10:08","pubTimestamp":1789610899,"startTime":"0","endTime":"0","summary":"消息面上，近期，AIDD利好催化密集。招商证券近期研报指出，CXO板块景气度明确上行。今年上半年国内CXO板块营收、归母净利润同比分别增长24.5%、52.7%，利润增速接近上一轮周期高点；在手订单与新签订单全面回暖，龙头上调全年指引。此外，AI制药有望重塑医药研发业态，提升药物研发效率，板块亦将受益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","06821","CXO","BK1141","BK1576","HK0000320264.USD","HK0000306701.USD","HK0000306685.HKD","BK4585","BK4588","BK1583","KCAI","01873","HK0000320223.HKD","02315","01548","BK1161","WX","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667218626","title":"生物制品及CXO行业集体与投资者互动 企业“出海”进阶 从产品输出迈向能力输出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667218626","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667218626?lang=zh_cn&edition=full","pubTime":"2026-09-16 00:16","pubTimestamp":1789488960,"startTime":"0","endTime":"0","summary":"9月15日，科创板细分行业集体业绩说明会之生物制品及CXO（医药外包服务）行业集体业绩说明会召开，多家上市公司高管出席。从投资者互动的情况中可知，对于生物制品及CXO行业上市公司，关注的主要事项集中在“出海”、研发等方面。在互动过程中，相关公司高管进行了详细解答。在相关上市公司的半年报和互动过程中，“加大海外市场拓展力度”等信息被频繁提及。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609163875135164.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609163875135164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667165628","title":"中信建投：内外需改善逐步传导订单与业绩 CXO有望进入新一轮增长阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2667165628","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667165628?lang=zh_cn&edition=full","pubTime":"2026-09-14 15:50","pubTimestamp":1789372227,"startTime":"0","endTime":"0","summary":"随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["WX","BK0276","601066","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513175","title":"东北证券：创新药BD和商业化持续兑现 CXO超预期，传统板块筑底拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666513175?lang=zh_cn&edition=full","pubTime":"2026-09-10 09:55","pubTimestamp":1789005326,"startTime":"0","endTime":"0","summary":"东北证券主要观点如下：创新药板块：海外创新药产业高景气延续，国产药企有望承接红利Pharma依托多元路径实现营收稳健增长，Biotech凭借BD和商业化释放业绩弹性。多家创新药企业2026H1业绩超预期增长，这与CXO板块公司的半年度业绩相印证，进一步确认了板块的中期产业趋势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0028","LNGR","000686","WX","CXO","06978","BK1161","159992","BK1574","BK0276","IBBQ","MEDX","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665934734","title":"分拆上市成利好？金斯瑞大反攻，飙升逾12%！华宝基金港股通医疗ETF（159137）标的指数涨近2%，CXO全线提振","url":"https://stock-news.laohu8.com/highlight/detail?id=2665934734","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665934734?lang=zh_cn&edition=full","pubTime":"2026-09-08 14:06","pubTimestamp":1788847560,"startTime":"0","endTime":"0","summary":"CXO概念集体走强，金斯瑞生物科技飙升逾12%，百奥赛图-B涨超9%，泰格医药、凯莱英涨超7%，药明合联涨超4%。港股通医疗ETF华宝标的指数CXO含量超50%，午后涨近2%！全链布局创新药，关注两大T+0交易利器：港股通医疗ETF华宝：被动跟踪港股通医疗主题指数，重仓创新药产业链，50%CXO+20%创新药，其中药明系占比超38%。港股通创新药ETF华宝：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-08/doc-inirayqy9498188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","CSD","SPIT","ACTV","FLHK","CXO","159828","159137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319763","title":"昊海生科：关于参加科创板2026年半年度生物制品及CXO行业集体业绩说明会的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319763","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319763?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，昊海生科发布公告称，公司计划于2026年9月15日15：00-17：00参加由上海证券交易所主办的科创板2026年半年度生物制品及CXO行业集体业绩说明会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxu6392948.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxu6392948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX","BK0239","KSTR","BK0251","688366"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665369630","title":"创新药三大指数上涨、ETF吸金，CXO及科研服务呈高景气度","url":"https://stock-news.laohu8.com/highlight/detail?id=2665369630","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665369630?lang=zh_cn&edition=full","pubTime":"2026-09-06 09:57","pubTimestamp":1788659820,"startTime":"0","endTime":"0","summary":"H股创新药指数2026上半年收入同比增长17.91%、归母净利润同比增长60.94%、扣非归母净利润同比增长30.73%。银河证券分析称，上半年行业利润增长显著快于收入，主要系创新药商业化收入及对外授权收入增加，高毛利业务占比大幅提升，同时CXO和科研服务呈高景气度，订单增长驱动前期产能建设和人员储备充分利用，摊薄固定成本并推动利润增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqvzvc0193188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","MEDX","BK4588","FDN","LNGR","BK1161","BK4585","IBBQ","WX","06978","CXO","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855519","title":"医疗器械迎业绩拐点？512170成功收红！AI4S带火港股CXO，金斯瑞涨超7%！港股通医疗ETF华宝逆市上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855519","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664855519?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:12","pubTimestamp":1788261120,"startTime":"0","endTime":"0","summary":"9月1日，A股港股医疗板块逆市表现，医疗ETF华宝、港股通医疗ETF华宝等相关品种热度再升温。医疗器械方面，英科医疗上半年营收、净利双增，迈瑞医疗利润降幅显著收窄至5.4%，联影医疗营收同比增长17%。中信建投研报指出，医疗器械行业迎来业绩修复拐点，2026Q2归母净利润实现四年首正增长，板块整体企稳回升。聚焦医疗器械+医疗服务，CXO含量超30%，兼顾脑机接口、AI医疗。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-01/doc-iniqipis4811448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159883","FLHK","BK1583","WX","512170","BK4588","BK4585","KCAI","PTH","LNGR","09996","MDEV","MEDX","HART","AGNG","RSPH","IEIH","CXO","GDOC","BK1100","BK1574","VXUS","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664896628","title":"招商证券： 需求释放 CXO板块景气度明确上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2664896628","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664896628?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:09","pubTimestamp":1788221376,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0276","BK0188","600999","BK1564","WX","BK0010","BK0183","BK0012","CXO","06099","BK1147","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766810","title":"CXO今天也是支棱起来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766810","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662766810?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:11","pubTimestamp":1787706660,"startTime":"0","endTime":"0","summary":"来源：硬核姬老板MACD金叉信号形成，这些股涨势不错！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-26/doc-inipqxha2247730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662731118","title":"中报再点火，CXO全线爆发！药明合联、凯莱英绩后狂飙，港股通医疗ETF（159137）爆量大涨，成交额激增超300%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662731118","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662731118?lang=zh_cn&edition=full","pubTime":"2026-08-25 19:41","pubTimestamp":1787658060,"startTime":"0","endTime":"0","summary":"CXO含量超50%的港股通医疗ETF华宝全天单边上行，日线强势“阳包阴”！24日，药明合联、凯莱英双双发布2026年中报，上半年经调整归母净利润均实现同比两位数增长，增速分别为37.4%、12.9%。药明合联上半年未完成总订单达22亿美元，同比大幅增长62.2%；凯莱英公司在手订单总额16.73亿美元，较去年同期增长53.77%，新签订单同比增长54.59%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-25/doc-inipprnk9691167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1141","BK0132","WX","LU2488822045.USD","02268","FLHK","002821","BK0239","LU1328615791.USD","SG9999014674.SGD","06821","BK1191","CXO","159137","159828"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662004362","title":"港股异动 | CRO概念股涨幅居前 海外CXO业绩普遍超预期 机构指全球需求复苏确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2662004362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662004362?lang=zh_cn&edition=full","pubTime":"2026-08-25 10:20","pubTimestamp":1787624451,"startTime":"0","endTime":"0","summary":"消息面上，IQVIA、Medpace、Lonza、三星生物等海外CXO龙头业绩密集披露，订单端强势反转，多家上调全年指引。湘财证券认为，近期CXO整体表现亮眼是全球医药融资回暖下产业基本面持续向好的全球性的趋势，中国CXO相关公司具备工程师红利将充分享受产业红利，在全球产业向好的趋势下持续性预计将较强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","LU0417516738.SGD","LU0140636845.USD","LU0181495838.USD","BK1610","LU0417516902.SGD","LU0979878070.USD","LU0456846285.SGD","LU1242518857.USD","LU0823426308.USD","BK1583","KCAI","LU0708995583.HKD","HK0000320264.USD","LU1794554557.SGD","HK0000320223.HKD","LU1880383366.USD","LU0856984785.SGD","BK1576","LU0823426480.USD","03347","BK4585","01548","LU0348825331.USD","LU1242518931.SGD","WX","LU0516423174.USD","LU0516422952.EUR","LU0051755006.USD","LU0456827905.SGD","LU0029874061.USD","VXUS","LU3063872942.SGD","LU0359201612.USD","BK1141","LU0327786744.USD","KURE","LU1688375341.USD","LU0307460666.USD","BK4588","LU0052750758.USD","LU0320764599.SGD","LU0516422440.USD","06821","LU2039709279.SGD","02269","LU0128526141.USD","BK1521","CXO","LU0572944931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200320","title":"医药外包概念盘初普升 凯莱英（06821）涨6.21% 机构指CXO行业景气上行逻辑不断夯实","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200320","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662200320?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:57","pubTimestamp":1787623040,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初普升，截至发稿，凯莱英 涨6.21%，金斯瑞生物科技涨4.78%，药明生物涨2.22%，维亚生物涨1.67%，泰格医药涨1.05%。消息面上，国金证券表示，CXO行业景气度持续向上，全球生物医药投融资回暖带动创新药研发投入提速，海内外龙头订单与业绩逐步兑现，行业景气上行逻辑不断夯实。头部CXO企业也主动融合AI能力，迭代实验与生产体系。在传统创新药需求叠加AI制药增量的共振之下，行业中长期成长空间进一步打开。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989237","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456846285.SGD","LU0348825331.USD","BK1161","CXO","LU0359201612.USD","BK1610","LU0140636845.USD","SG9999002463.SGD","LU0516422366.SGD","BK0132","BK1515","LU0359202008.SGD","LU0823426308.USD","LU0181495838.USD","01873","LU0708995583.HKD","LU0819121731.USD","HK0000306685.HKD","LU0856984785.SGD","LU0051755006.USD","LU1720050803.USD","LU0029874061.USD","KURE","01548","03347","LU0307460666.USD","LU1880383366.USD","HK0000320223.HKD","159938","LU0052750758.USD","BK1191","LU0516423091.SGD","LU0456827905.SGD","LU1242518857.USD","SG9999002562.SGD","06821","BK1589","LU1242518931.SGD","WX","HK0000320264.USD","LU0039217434.USD","LU1794554557.SGD","09939","LU0516422440.USD","02269","LU0516422952.EUR","LU0326950275.SGD","LU0979878070.USD","002821","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxiapptec.com","stockEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":-0.0365},{"period":"3month","weight":0.0183},{"period":"6month","weight":-0.0292},{"period":"ytd","weight":-0.0292}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"药明康德在开曼群岛注册成立于2004年6月3日，没有显著的资产或它自己的业务。几乎所有在中国开展的业务都是通过其主要运营子公司，WXAT，一家于2000年12月成立的药明康德新药开发有限公司。公司的核心业务是提供发现化学服务在药物发现过程的开始合成的小分子。该公司是一家全球领先的制药、生物技术以及医疗器械研发外包服务公司。公司的核心业务是在药物发展过程的开始阶段为合成小分子提供发现化学服务。公司主要在中国和美国经营业务。公司在研发过程中提供一系列全方位的实验室及制造服务给客户，这些客户包括许多世界一流的制药、生物技术和医疗器械公司。公司的服务旨在帮助全球客户缩短时间，并通过提供具有成本效益和高效率的外包解决方案，降低药品和医疗器械的研发成本。","exchange":"CBOE","name":"Corgi All World 2x Daily ETF","nameEN":"Corgi All World 2x Daily ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corgi All World 2x Daily ETF(WX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Corgi All World 2x Daily ETF(WX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Corgi All World 2x Daily ETF,WX,Corgi All World 2x Daily ETF股票,Corgi All World 2x Daily ETF股票老虎,Corgi All World 2x Daily ETF股票老虎国际,Corgi All World 2x Daily ETF行情,Corgi All World 2x Daily ETF股票行情,Corgi All World 2x Daily ETF股价,Corgi All World 2x Daily ETF股市,Corgi All World 2x Daily ETF股票价格,Corgi All World 2x Daily ETF股票交易,Corgi All World 2x Daily ETF股票购买,Corgi All World 2x Daily ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corgi All World 2x Daily ETF(WX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Corgi All World 2x Daily ETF(WX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}